Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017 Pharmaceutical Investing
RedHill Biopharma Announces Positive and Unanimous DSMB Recommendation for Continuation of Phase III Study with RHB-104 for Crohn’s Disease Pharmaceutical Investing
GB Sciences Licenses Patent To Develop New Cannabis-Based Therapies For The Treatment Of Heart Disease Pharmaceutical Investing
MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or Refractory CLL or SLL Previously Treated with a BTK Inhibitor Life Science Investing
Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency Pharmaceutical Investing
RedHill Biopharma Announces Phase IIa 48-Week Final Results for RHB-104 in Multiple Sclerosis Pharmaceutical Investing
